ABSTRACT
The use of vasoconstrictor agents like vasopressin during laparoscopic myomectomy reduces blood loss during surgery and reduces operative time. However, certain side effects related to the cardiovascular system have also been reported with its use. These side effects could possibly be due to inadvertent intravascular injection of the drug. The author aims to describe a new design of an injection needle, Pisat's Visual Vasopressor Injection Needle (VVIN) that can be used during laparoscopic myomectomy to reduce the likelihood of an inadvertent intravascular injection of a vasoconstrictor solution.

Keywords: Fibroid, Laparoscopy, Myomectomy, Vasopressin.

INTRODUCTION
It is common practice during laparoscopic myomectomy to inject a diluted solution of a vasoconstrictor agent into the fibroid to reduce intraoperative blood loss.1 The use of such vasoconstrictive agents has also been associated with intraoperative hemodynamic fluctuations,2 and very occasionally may also cause severe morbidity or mortality. These side effects could be due to its inadvertent injection into the blood vessels over the fibroid. These side effects have resulted in the drug not being commercialized in some countries across the world.

SUMMARY
The standard laparoscopic myomectomy needle is about 33 cm in length and is completely opaque. Predominantly, the fibroid vasculature consists of thin-walled capillaries and small veins.3 Even if the surgeon does mistakenly puncture a blood vessel, the column of blood is extremely unlikely to rise to a distance high enough to discolor the fluid in the syringe red.

By adding a small, transparent area at the proximal end of the instrument, a blood-stained aspirate can be immediately seen in case the needle has punctured a vessel.4 The needle can then be repositioned at another site over the fibroid. This significantly reduces the possibility of injecting the vasoconstrictor solution in the vascular channels over the fibroid.

DETAILED DESIGN OF PISAT’S VVIN

The VVIN is a 33 cm long and 5 mm wide hollow needle, similar to the existing needle that is used for injecting vasopressin solution during laparoscopic myomectomy. At one end of the instrument, which remains outside the abdomen, is a Luer lock hub that attaches to a standard syringe. At the other end, which is inserted into the abdomen, the VVIN has a disposable and detachable tip which can be screwed on to the main shaft (Fig. 1).

THE VVIN TIP
The disposable VVIN tip has a 1 cm long transparent plastic cylindrical body and a 2.5 cm long metallic needle tip. The metallic shaft can be sterilized by autoclaving, and the transparent tip is disposable.

USING THE VVIN
The disposable tip is fixed over the shaft and the assembly is flushed with diluted vasopressin solution. After choosing a suitable site over the fibroid, as per the surgeon’s preference, the VVIN is thrust into the subcapsular plane. On aspirating with a syringe, if the tip of the needle has penetrated a blood vessel, the plastic hub of the VVIN shows a blood-stained aspirate (Fig. 2). However, if the
the aspiration shows no blood and vasopressin can be injected safely (Fig. 3).

EFFICACY

Using a VVIN, a volume of just 0.03 mL of blood is sufficient to detect a vascular puncture. This is lesser than one single drop of blood (approximately 0.05 mL), and about 27 times more sensitive than a regular injection needle, which requires about 0.8 mL of blood to show up as a positive aspirate in the syringe. A prospective randomized study published by Pisat and van Herendael demonstrated significantly lesser fluctuations in pulse and blood pressure with the use of a VVIN as compared with a regular 5 mm myoma infiltration needle, with no adverse cardiovascular effects.

The VVIN has several other applications than laparoscopic myomectomy. It can be used for injecting vasopressin before adenomyoma removal, during laparoscopic ovarian cystectomy for endometriomas, in cesarean scar ectopic pregnancy for devascularizing the uterine myometrium, and also for salpingotomy in cases of ectopic pregnancy.

The likelihood of serious life-threatening side effects due to vasopressin injection during laparoscopic myomectomy is not very frequent. This may be because a diluted solution of vasopressin is used. (The author uses 20 units of vasopressin diluted in 200 mL of normal saline, at an effective concentration of 0.01 U/mL). However, occasional catastrophic incidents have been reported even at low concentrations. These could be minimized or nullified completely by using a VVIN. This may be a suitable alternative to stopping the usage of a relatively inexpensive drug that causes significant reduction in overall blood loss during surgery.

Using a VVIN would also provide documentary evidence that the surgeon has taken adequate care to avoid an intravascular injection, and thus may become a legal requirement in the future.

A patent application for the device has been filed both in India (Application no 201721001762) and internationally (PCT/IN/2017/050259). A worldwide analysis of patent records has confirmed that no similar instrument for use in laparoscopic myomectomy exists till date, making this invention a worldwide first. More details, case studies, and videos can be found online on www.pisatsvvin.com.

REFERENCES